VisionGate, Inc
- Home
- Companies
- VisionGate, Inc
- Articles
3 Articles found
VisionGate, Inc articles
The Non-Intrusive LuCED Test for Detection of Early-Stage Lung Cancer: A Subgroup Analysis for Chronic Obstructive Pulmonary Disease (COPD)
Introduction
VisionGate’s LuCED® test for lung cancer measures 934 features in each cell imaged in 3D by the Cell- CT™. Sensitivity and specificity, both exceeding 90%, have been reported (Wilbur, et. al., Cancer Cytopathology, 123:9,
VisionGate’s LuCED® test for lung cancer measures 934 features in each cell imaged in 3D by the Cell- CT™. Sensitivity and specificity, both exceeding 90%, have been reported (Wilbur, et. al., Cancer Cytopathology, 123:9,
Aug. 3, 2021
VisionGate’s Non-Intrusive Testing, Patented Cell-CT Imaging and AI-Powered Cancer Detection Work Together to Deliver Early Detection of Lung Cancer.
VisionGate’s mission is backed by cutting-edge technology that is designed to save lives through early detection and prevention of lung cancer. VisionGate’s breakthrough technologies include non-intrusive testing, 3D cell imaging and AI-powered cancer early detection that work together to deliver effici
Oct. 2, 2021
VisionGate, a Breakthrough Liquid-biopsy Technology Company, Leads the Battle Against Lung Cancer through Early Detection Technology with a Simple, Non-Intrusive Sputum Test.
VisionGate wants you to live your life with peace of mind. That’s why we’ve launched a new website that makes it easy for you to learn more about our advanced lung cancer detection technology. Our new site also features resources to help you better understand the different types
Sep. 2, 2021